Since tau pathologic burden strongly correlates with the severity of neurodegeneration as well as clinical phenomenology, tau has been the focus of therapeutic development, with multiple tau-directed therapeutics evaluated in clinical trials of Alzheimer’s disease and other tauopathies (3, 4). This evidence concerns the gene MAPT and Alzheimer disease.